The FDA awarded Breakthrough Device Designation to Gene Solutions’ SPOT-MAS 10 multicancer early detection assay. The blood-based, adjunctive lab-developed test screens asymptomatic adults 40 and older for 10 cancer types from cfDNA using machine learning analysis of methylation and fragmentomic signatures. Gene Solutions said SPOT-MAS 10 includes breast, lung, liver, colorectal and gastric cancers plus five aggressive but less common malignancies. The company also disclosed a partnership with Pangea Laboratories to oversee U.S. analytical and clinical validation work, potentially leveraging Pangea’s Irvine lab for testing. Breakthrough designation can accelerate development and clarify regulatory pathways for next-generation screening platforms, and it increases scrutiny on clinical performance evidence in real-world screening populations.